Navigation Links
United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
Date:10/10/2011

SILVER SPRING, Md., Oct. 10, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced that its subsidiary, Unither Virology, LLC, has been awarded a contract for up to approximately $45 million under a Broad Agency Announcement from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for studies directed at the development of a broad-spectrum antiviral drug based on its glycobiology antiviral platform.  Based on the support from this contract, approximately 20 jobs will be created at Unither Virology's headquarters in Silver Spring, Maryland, with additional jobs created at subcontractor organizations.

"I'm pleased with the development of our broad-spectrum antiviral program, which is in the preclinical stage," remarked Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "The overall objective for this partnership with NIH is to develop a safe and orally available broad-spectrum antiviral drug to treat viruses such as dengue and influenza.  Dengue is a painful mosquito-borne tropical fever suffered by millions of patients worldwide each year, and this program may help provide a path to treatment.  It is also rewarding to see how our industry generates dozens of jobs when the science data justify expanding a program to its next stage of growth."

The contract provides for up to approximately $45 million in total funding over five years.  The base period of 42 months includes approximately $10.6 million in funding.  The remaining funds are allocated to eight milestone-based options.  Funding will support the development of a candidate compound through preclinical safety and efficacy studies toward potential clinical trials against dengue, as well as preclinical studies to develop additional data against influenza.

'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Full-day "United Nations" Online Investor Conference: October 6th at RetailInvestorConferences.com
2. United Therapeutics Corporation Reports Second Quarter 2011 Financial Results
3. FDA Advisory Panel Unanimously Recommends Approval of EXCOR(R) Pediatric Ventricular Assist Device for Use in the United States
4. Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom
5. United Therapeutics Corporation To Announce Second Quarter 2011 Financial Results Before Market Open on Thursday, July 28, 2011
6. United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial
7. United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results
8. United Therapeutics Corporation to Announce Fourth Quarter and Annual 2010 Financial Results Before Market Open on Tuesday, February 15, 2011
9. United Therapeutics Corporation Reports Third Quarter 2010 Financial Results
10. United Therapeutics Corporation to Announce Third Quarter 2010 Financial Results Before Market Open on Thursday, October 28, 2010
11. Sangart, Inc. Receives $1.1 Million Grant Award from the United States Department of Defense for Further Development of MP4 Molecule in Trauma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... Global Resorcinol ... premium industry insights on the global resorcinol industry. The report highlights the various ... vivid market scenarios and analysis of primary and secondary inputs from the existing ...
(Date:7/31/2015)... KONG , July 31, 2015 China ... China,s leading provider of cord ... stem cell storage services, today announced that the Company ... the U.S. Securities and Exchange Commission. The filed Form ... ended March 31, 2015. The Form 20-F can be ...
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is ... of partially hydrolyzed gluten in foods, has been accepted by AOAC International as ... Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a ...
(Date:7/30/2015)... , ... July 31, 2015 , ... Ralco is honored ... at the Lyon County Fair to be held August 5-9 in Marshall. The Ralco ... their meals come from and how agriculture impacts their daily lives. This unique exhibit ...
Breaking Biology Technology:Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4China Cord Blood Corporation Files Its Annual Report on Form 20-F 2RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2
... , DURHAM, N.C., Aug. 12 Oxygen Biotherapeutics, Inc. (OTC Bulletin ... 10-K for the fiscal year ended April 30, 2009. In addition to being available ... v , the 10-K can be downloaded from the company website at ... the Investors page. , , For the year ended April 30, ...
... , , LYNBROOK, N.Y., Aug. 12 ... company developing first in class collagenase-based products, today announced its ... , , "We were very pleased ... with Priority Review for XIAFLEX(TM) for the treatment of Dupuytren,s ...
... , , SAN DIEGO, Aug. 12 ... results for the three and six months ended June 30, 2009. , ... have the capital to complete and submit a New Drug Application (NDA) ... said Brian M. Culley, Principal Executive Officer at ADVENTRX. "Our financial ...
Cached Biology Technology:Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009 2Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009 3BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 5BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 6ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 2ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 3ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 4ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 5ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 6ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 7
(Date:7/31/2015)... , Kina, 31. juli 2015 Den 10. ... afholdt af BGI fra den 22. - 25. oktober i ... Konferencen fejrer sin 10-års fødselsdag i år. Siden starten ... indflydelsesrige årlige møder på ,omik,-feltet, og er en af ... ICG-10 fokuserer på nylige gennembrud og fremskridt ...
(Date:7/31/2015)... China , 31 de julio de 2015 /PRNewswire/ ... Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 de ... . La conferencia celebra su décimo aniversario ... ha convertido en una de las reuniones anuales más ... y es una de las conferencias científicas más dinámicas, ...
(Date:7/31/2015)... , 31 de julho de 2015 A ... www.icg-10.org ) será realizada pela BGI de 22-25 de outubro ... A conferência está celebrando seu 10 o. ... a ICG se tornou uma das reuniões mais influentes ... encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... to control lens development in mice and humans is also ... as neurobiologists of the Max Delbrck Center for Molecular Medicine ... in which they had removed the c-Maf gene in the ... human carriers of a mutant c-Maf gene. People with such ...
... two new European projects focusing on type 2 diabetes. ... and strategies for preventing the disease. Focus is on ... effects of changes in lifestyle. The goal includes planning ... diabetes and exploiting the results in a major European ...
... Airborne gases get sucked into stubborn smog particles from ... Irvine and other researchers published today in the ... The results could explain a problem identified in recent ... Protection Agency, California air regulators and others significantly underestimate ...
Cached Biology News:The molecular basis of touch sensation 2VTT searches for novel biomarkers and targets for preventing or treating Type 2 diabetes 2Gases drawn into smog particles stay there, UCI-led study reveals 2
Agarose-LE, 500 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
Request Info...
FITC~Bovine Serum Albumin...
Biology Products: